BRIEF-Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics; iX Biopharma to Receive a $9M Upfront Plus Up to $239M in Milestone Payments Plus Royalties
BRIEF-IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics
IX Biopharma Trims FY21 Loss Amid Robust Product Demand in China
Top Dividend Stocks to Watch Out for in August 2021
Singapore's mid-cap stocks have led their counterparts in the Asia-Pacific region so far this year.
As of March 19, 2021, the 63 Singapore mid-cap stocks with a market capitalization between S $1 billion and S $5 billion had an average total return of 12 per cent, with a median total return of 6 per cent.